Schrodinger, INC 8-K filings

Schrodinger, Inc. announced it received approximately $57 million in cash following the completion of Eli Lilly and Company's acquisition of Ajax Therapeutics, Inc., a company co-founded by Schrodinger.

Schrodinger, Inc. has formalized the separation of its Chief Commercial Officer, Mannix Aklian, outlining terms for continued benefits and payments.

Schrodinger, Inc. reported the departure of its Chief Commercial Officer and reaffirmed its financial and operational guidance for the second quarter and full year 2026.

Schrodinger, Inc. announced the appointment of Therese Abrams as its new Principal Accounting Officer, succeeding Jenny Herman who will depart after a transition period.

Schrdinger, Inc. announced robust full-year 2025 financial results, including 23% total revenue growth and a reduced net loss, alongside a strategic shift to hosted software and a path to positive adjusted EBITDA by 2028.

Schrodinger reported robust third-quarter 2025 financial results with significant revenue growth, reduced net loss, and a strategic shift in its therapeutics R&D model.

Schrodinger, Inc. finalized a separation agreement with former CFO Geoffrey Porges, detailing severance, equity vesting, and bonus terms.

Schrodinger, Inc. reported a 16% increase in Q2 2025 total revenue to $54.8 million, maintained full-year revenue guidance, and lowered operating expense guidance.

Schrodinger, Inc. announced that its stockholders approved all three proposals at the 2025 Annual Meeting, including the election of four Class II directors, the advisory vote on executive compensation, and the ratification of KPMG LLP as the independent auditor.

Schrödinger, Inc. announces the appointment of Richie Jain as its new Executive Vice President and Chief Financial Officer, effective May 16, 2025, succeeding Geoffrey Porges who will remain as an advisor through June 6, 2025.

Schrödinger, Inc. announces a restructuring plan involving workforce reduction and cost-cutting measures to improve its cash burn rate and operational efficiency.

Schrödinger's first quarter 2025 results show a 63% increase in total revenue, driven by strong performance in both software and drug discovery segments, with initial clinical data for SGR-1505 expected in June.

Schrödinger, Inc. has reached a settlement in a derivative lawsuit challenging its historical compensation practices for non-employee directors, agreeing to implement corporate governance reforms and pay $390,000 in attorneys' fees.

Schrödinger, Inc. has elected Bridget van Kralingen, a seasoned executive with experience at IBM and Motive Partners, to its Board of Directors, effective immediately.

Schrödinger announces positive Q4 and full-year 2024 financial results, highlighted by a 13.3% increase in software revenue for the year, and anticipates further growth in 2025, along with an expanded research collaboration with Eli Lilly.

Schrödinger reported its third quarter 2024 financial results, highlighted by a new $150 million upfront collaboration with Novartis and updated full-year financial guidance.

Schrödinger has entered into a research collaboration and license agreement with Novartis, potentially worth up to $2.422 billion plus royalties.

Schrodinger, Inc. has entered into a new Master License Agreement with Columbia University, consolidating and updating previous licensing arrangements for key software and patents.

Schrödinger announced a 21% increase in software revenue and significant progress in its drug discovery programs for the second quarter of 2024.

Schrodinger Inc. stockholders approved amendments to the company's equity incentive and employee stock purchase plans, along with the election of three Class I directors, at their annual meeting on June 18, 2024.

Schrödinger's Q1 2024 results show a decrease in total revenue due to a large collaboration milestone in the previous year, but software revenue saw a modest increase, and the company's drug pipeline continues to advance.

Schrodinger Inc. has entered into an amended agreement with Leerink Partners LLC to potentially sell up to $250 million of its common stock through an at-the-market offering.

Schrödinger announced a 44% increase in fourth-quarter software revenue and 20% total revenue growth for 2023, alongside a positive outlook for 2024.